Transferrin Receptor-Targeted Anti-Amyloid Antibody Enhances Brain Delivery and Mitigates ARIA

Alzheimer’s Therapy Delivery Boosted with Engineered Antibody

FDA-approved Alzheimer’s immunotherapies have shown some benefit, but serious side effects and poor brain delivery continue to pose challenges. The newly designed antibody transport vesicle produced by Michelle Pizzo, PhD, from Denali Therapeutics, and colleagues at Denali and Genentech, holds promise as a potential solution to these challenges. The team detailed their work in a paper published in Science titled, “Transferrin receptor-targeted a…

Transferrin Receptor-Targeted Anti-Amyloid Antibody Enhances Brain Delivery and Mitigates ARIA

Researchers developed an antibody transport vehicle targeting the transferrin receptor for brain delivery of amyloid-β antibodies that significantly reduced amyloid-related imaging abnormality (ARIA)-like lesions and improved plaque target engagement in a mouse model of amyloid deposition. [Science] AbstractGraphical Abstract